Climate-resilient agriculture uses biotechnology, biofertilizers, biopesticides, genome-edited crops, and AI-driven tools to ...
The company said it expects total revenue of between $450 million and $475 million this year, up from the $290 million to ...
FibroBiologics submits IND application with US FDA to initiate clinical trials of CYPS317 in psoriasis patients: Houston Saturday, January 3, 2026, 11:00 Hrs [IST] FibroBiologics ...
Barchart on MSN
The FDA just snubbed Corcept Therapeutics. Should you buy the dip in CORT stock or stay far away?
Corcept Therapeutics (CORT) crashed on Dec. 31 after the Food and Drug Administration (FDA) rejected its application for ...
ContentsInnovationNew biopolymersFashion demands betterRegulation & policyTrump’s overhaulA new EU bioeconomy ...
23hon MSN
‘Biosecure Act’: New bill forces California biotech firms to cut ties with Chinese companies
Most biotech firms will be forced to reevaluate foreign relationships and re-route supply chains, or hope for a federal ...
BioAtla and GATC Health announce $40 million SPV transaction to advance ozuriftamab vedotin into a registrational trial for 2L+ OPSCC: San Diego Saturday, January 3, 2026, 18:00 H ...
Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Jan. 2, 2026 /CNW/ — Equity Insider News Commentary – The gene therapy market is surging toward $36.55 billion by ...
Corcept sought FDA approval despite finding relacorilant was statistically no better than placebo in one of two Phase III ...
Street research is expected for four companies in the week ahead, and six lock-up periods will be expiring.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback